Search Results for: Residues resulting from treatment of animal
, versus percent in the placebo group (p< ) of patients treated with upadacitinib / mg, / percent achieved viga-ad / , respectively, versus percent of patients receiving placebo (p< ) "we are encouraged by these results that reaffirm the data from measure up and underscore the potential impact rinvoq
"atopic dermatitis is more than a rash or itchy skin. many people living with moderate to severe forms continue to suffer from significant physical and emotional burden of the disease," said alan irvine, m.d., d.s.c., professor of dermatology, trinity college dublin, ireland and lead study investigator...
https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase-3-study-for-atopic-dermatitis.htm